ESTRO 2025 - Abstract Book

S1605

Clinical – Mixed sites & palliation

ESTRO 2025

the 8 (15.4%) cases of local failure, 6 (11.5%) were in-field, while 2 (3.8%) were marginal-field (progression in the portion of adrenal gland not included in the PTV) (figure 1). A PTV prescribed dose ³8 Gy (HR 0.12 [95% CI 0.01-0.90], p = 0.04) and a IGTV BED 10 ≥72 Gy (HR 0.10 [95% CI 0.01-0.84], p = 0.03) were correlated with improved LPFS. One- and 2-year DFS rate was 33.9% (95% CI 22.5-51.1) and 23.5% (95% CI 13.6-40.6), respectively, and the corresponding OS rates were 66.0% (95% CI 52.8-82.5) and 74.0% (95% CI 37.5-70.3), respectively. No SBRT-related adverse events G≥3 occurred, and no cases of adrenal insufficiency were recorded, including in high -risk patients (5 patients with bilateral AGMs irradiation, and 3 patient treated after contralateral adrenalectomy).